ERBB2 and breast cancer: When it comes to the role of the immune system in BC, distinct immune biology can be observed in different BC subtypes, with HER2-positive and triple negative tumors (TNBC) typically having increased immune infiltration in comparison to ER-positive tumors, making those more immunogenic and, by consequence, targetable by immunotherapy [66, 67].